TY - JOUR
T1 - Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells.
AU - Abreu, Soraia
AU - Hampton, Thomas
AU - Hoffman, Evan
AU - Dearborne, Jacob
AU - Ashare, Alix
AU - Sidhu, Karatatiwant
AU - Mattheews, Dwight
AU - McKenna, David
AU - Amiel, Eyal
AU - Barua, Jayita
AU - Krasnodembskaya, Anna
AU - English, Karen
AU - Mahon, Bernard P.
AU - Dos Santos, Claudia
AU - Cruz, Fernanda
AU - Chambers, Daniel
AU - Liu, Kathleen D.
AU - Matthay, Michael A.
AU - Cramer, Robert
AU - Stanton, Bruce
AU - Rocco, Patricia
AU - Wargo, Matthew
AU - Weiss, Daniel
AU - Rolandsson Enes, Sara
PY - 2020/9/9
Y1 - 2020/9/9
N2 - Growing evidence demonstrates that human mesenchymal stromal cells (MSCs) modify their in vivo anti-inflammatory actions depending on the specific inflammatory environment encountered. Understanding this better is crucial to refine MSC-based cell therapies for lung and other diseases. Using acute exacerbations of cystic fibrosis (CF) lung disease as a model, the effects of ex vivo MSC exposure to clinical bronchoalveolar lavage fluid (BALF) samples, as a surrogate for the in vivo clinical lung environment, on MSC viability, gene expression, secreted cytokines, and mitochondrial function was compared to effects of BALF collected from healthy volunteers. CF BALF samples which cultured positive for Aspergillus sp. (Asp) induced rapid MSC death, usually within several hours of exposure. Further analyses suggested the fungal toxin gliotoxin as a potential mediator contributing to CF BALF-induced MSC death. RNA sequencing analyses of MSCs exposed to either Asp+ or Asp- CF BALF samples identified a number of differentially expressed transcripts, including those involved in interferon-signaling, anti-microbial gene expression, and cell death. Toxicity did not correlate with bacterial lung infections. These results suggest that the potential use of MSC-based cell therapies for CF or other lung diseases may not be warranted in the presence of Aspergillus.
AB - Growing evidence demonstrates that human mesenchymal stromal cells (MSCs) modify their in vivo anti-inflammatory actions depending on the specific inflammatory environment encountered. Understanding this better is crucial to refine MSC-based cell therapies for lung and other diseases. Using acute exacerbations of cystic fibrosis (CF) lung disease as a model, the effects of ex vivo MSC exposure to clinical bronchoalveolar lavage fluid (BALF) samples, as a surrogate for the in vivo clinical lung environment, on MSC viability, gene expression, secreted cytokines, and mitochondrial function was compared to effects of BALF collected from healthy volunteers. CF BALF samples which cultured positive for Aspergillus sp. (Asp) induced rapid MSC death, usually within several hours of exposure. Further analyses suggested the fungal toxin gliotoxin as a potential mediator contributing to CF BALF-induced MSC death. RNA sequencing analyses of MSCs exposed to either Asp+ or Asp- CF BALF samples identified a number of differentially expressed transcripts, including those involved in interferon-signaling, anti-microbial gene expression, and cell death. Toxicity did not correlate with bacterial lung infections. These results suggest that the potential use of MSC-based cell therapies for CF or other lung diseases may not be warranted in the presence of Aspergillus.
U2 - 10.1152/ajplung.00218.2020
DO - 10.1152/ajplung.00218.2020
M3 - Article
C2 - 32901521
JO - American Journal of Physiology - Lung Cellular and Molecular Physiology
JF - American Journal of Physiology - Lung Cellular and Molecular Physiology
SN - 1040-0605
ER -